Comparative Pharmacology
Head-to-head clinical analysis: ANTRENYL versus TROSPIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTRENYL versus TROSPIUM CHLORIDE.
ANTRENYL vs TROSPIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antrenyl (oxyphenonium bromide) is a quaternary ammonium anticholinergic agent that competitively blocks acetylcholine at muscarinic receptors in smooth muscle, exocrine glands, and the CNS, leading to reduced gastrointestinal motility and secretion.
Tropium chloride is a quaternary ammonium compound that acts as a competitive antagonist at muscarinic acetylcholine receptors (M1, M2, M3), thereby reducing smooth muscle tone in the bladder, decreasing detrusor overactivity, and increasing bladder capacity.
50 mg orally 3 times daily initially, then adjust to 50-100 mg 3 times daily; 20 mg intramuscularly or intravenously every 4-6 hours as needed.
20 mg orally twice daily, extended-release 60 mg orally once daily in the morning.
None Documented
None Documented
2-4 hours (terminal), requiring q6-8h dosing for sustained anticholinergic effect
Terminal elimination half-life: 10-20 hours (mean 14 hours); clinical context: supports twice-daily dosing
Renal (80% as unchanged drug and metabolites), biliary/fecal (20%)
Renal: 65% (40% unchanged, 25% as metabolites); Fecal/Biliary: 35% (primarily via bile)
Category C
Category A/B
Anticholinergic
Anticholinergic